Longevity & Aging · Metabolic & Cardiometabolic
rapamycin increases healthspan and lifespan
In plain terms: Is rapamycin proven to make animals live longer also proven to extend human lifespan?
Part of: • Aging
Robustly extends lifespan/healthspan in mice across independent labs, but in humans only short-term safety and immune-biomarker data exist — no human longevity outcome, exactly as Attia's hedged framing states.
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Animal studies (Animal)
How the studies fall
What the evidence shows
In mice this is robust and replicated across independent labs, with transient mid-life treatment extending life expectancy substantially and improving healthspan measures. In humans there is only short-term safety and biomarker data: the PEARL trial missed its primary visceral-adiposity endpoint, and rapamycin causes measurable glucose intolerance in mice, so the trade-offs are unresolved.
The evidence (14)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Moel M, Harinath G, Lee V, Nyquist A, Morgan SL, Isman A, Zalzala S 2025 · Aging (Albany) | RCT | mixed | low | HUMAN: 48-wk intermittent low-dose rapamycin in healthy adults (PEARL trial) — primary visceral-adiposity endpoint largely null, broadly safe; no longevity outcome, confirms human data remains short-term/insufficient. |
| Bitto A, Ito TK, Pineda VV, LeTexier NJ, Huang HZ, Sutlief E, Tung H, Vizzini N, Chen B, Smith K, Meza D, Yajima M, Beyer RP, Kerr KF, Davis DJ, Gillespie CH, Snyder JM, Treuting PM, Kaeberlein M 2016 · eLife | animal | supports | high | MOUSE: transient 3-month rapamycin in middle-aged mice increased life expectancy up to 60% and improved healthspan measures. |
| Kell L, Jones EJ, Gharahdaghi N, Wilkinson DJ, Smith K, Atherton PJ, Simon AK, Cox LS, Alsaleh G 2026 · Aging Cell | mechanism | supports | low | Human RCT (older adults): low-dose rapamycin reduced p21 (immune-senescence surrogate) - a biomarker signal only, NOT a healthspan/lifespan outcome; consistent with human-benefit-not-yet-established. |
| Zerdka J, Brasse P, Piszka M, Kwapien E, Kubicka M, Bartkowski J, Banach J, Dacyl H, Owczarska A 2025 · Cureus | observational | supports | low | Review states rapamycin/analogs 'consistently prolong life in numerous animal models,' improving metabolism, heart function, cognition, immunity; in human trials, low-dose rapamycin 'improves immune response, reduces markers of sk |
| Weiss R, Fernandez E, Liu Y, Strong R, Salmon AB 2018 · Aging (Albany NY) | animal | mixed | moderate | Rapamycin caused measurable glucose intolerance in mice (partly reversible with metformin), highlighting metabolic trade-offs that temper the healthspan claim. |
| Strong R, Miller RA, Bogue M, Fernandez E, Javors MA, Libert S, Marinez PA, Murphy MP, Musi N, Nelson JF, Petrascheck M, Reifsnyder P, Richardson A, Salmon AB, Macchiarini F, Harrison DE 2020 · Aging Cell | animal | supports | high | MOUSE: late-life (20mo) rapamycin raised survival in genetically heterogeneous mice; NIA-ITP multi-site design, sex-specific dosing effects. |
| Mannick JB, Morris M, Hockey HP, Roma G, Beibel M, Kulmatycki K, Watkins M, Shavlakadze T, Zhou W, Quinn D, Glass DJ, Klickstein LB 2018 · Sci Transl Med | RCT | mixed | high | HUMAN: TORC1 inhibitor (RAD001+BEZ235) in 264 elderly reduced infection rates and boosted immunity over 6 wks — biomarker/healthspan proxy, NOT a lifespan outcome; supports human tolerability, confirms absence of longevity endpoint. |
| Strong R, Miller RA, Antebi A, Astle CM, Bogue M, Denzel MS, Fernandez E, Flurkey K, Hamilton KL, Lamming DW, Javors MA, de Magalhães JP, Martinez PA, McCord JM, Miller BF, Müller M, Nelson JF, Ndukum J, Rainger GE, Richardson A, Sabatini DM, Salmon AB, Simpkins JW, Steegenga WT, Nadon NL, Harrison DE 2016 · Aging Cell | animal | supports | high | ITP dose-finding confirmed reproducible lifespan extension by rapamycin (and rapamycin+metformin) in heterogeneous mice, underscoring robustness of the animal effect. |
| Birkisdóttir MB, Jaarsma D, Brandt RMC, Barnhoorn S, van Vliet N, Imholz S, van Oostrom CT, Nagarajah B, Portilla Fernández E, Roks AJM, Elgersma Y, van Steeg H, Ferreira JA, Pennings JLA, Hoeijmakers JHJ, Vermeij WP, Dollé MET 2021 · Aging Cell | animal | contradicts | high | Progeroid DNA-repair-deficient mice: rapamycin did NOT extend lifespan/healthspan (unlike dietary restriction) - animal benefit is not universal across models. |
| Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, Pahor M, Javors MA, Fernandez E, Miller RA 2009 · Nature | animal | supports | high | Rapamycin started late in life extended median and maximal lifespan in genetically heterogeneous mice at three independent sites, the landmark mammalian result. |
| Coleman AE, Creevy KE, Anderson R, Reed MJ, Fajt VR, Aicher KM, Atiee G, Barnett BG, Baumwart RD, Boudreau B, Cunningham SM, Dunbar MD, Ditzler B, Ferguson AM, Forsyth KK, Gambino AN, Gordon SG, Hammond HK, Holland SN, Iannaccone MK, Illing K, Kadotani S, Knowles SA, MacLean EL, Maran BA, Markovic LE, McGrath S, Melvin RL, Mueller MS, Nelson OL, Olby NJ, Pancotto TE, Parsley E, Potter BM, Prescott JO, Saunders AB, Sawyer HM, Scansen BA, Schmid SM, Smith CC, Tjostheim SS, Tolbert MK, Tropf MA, Visser LC, Ward JL, Wesselowski SR, Windsor RC, Yang VK, Ruple A, Promislow DEL, Kaeberlein M, Dog Aging Project Consortium 2025 · Geroscience | animal | supports | high | Describes the TRIAD study protocol: a prospective, randomized, placebo-controlled trial testing whether rapamycin prolongs lifespan and improves healthspan metrics in healthy middle-aged dogs — the first rigorous test of a pharmac |
| Herrera JJ, Pifer K, Louzon S, Leander D, Fiehn O, Day SM, Miller RA, Garratt M 2023 · J Gerontol A | animal | supports | moderate | MOUSE: early or late-life rapamycin improved physical performance and reduced cardiac hypertrophy in aged mice (healthspan, not lifespan endpoint). |
| Arriola Apelo SI, Pumper CP, Baar EL, Cummings NE, Lamming DW 2016 · J Gerontol A | animal | supports | moderate | MOUSE: intermittent rapamycin from 20 months extended lifespan in female C57BL/6J mice with reduced metabolic side effects. |
| Mannick JB, Del Giudice G, Lattanzi M, Valiante NM, Praestgaard J, Huang B, Lonetto MA, Maecker HT, Kovarik J, Carson S, Glass DJ, Klickstein LB 2014 · Sci Transl Med | RCT | mixed | moderate | HUMAN: RAD001 improved influenza vaccine response about 20% in elderly — immunosenescence proxy only, no aging/lifespan outcome. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.